CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager^® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy.

Presentation Details
Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers
Presenter: Leonardo Borras, Chief Scientific Officer
Date: April 23, 2024

About CDR-Life
CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.